Published in Mol Pharm on January 24, 2013
Targeted nanotechnology for cancer imaging. Adv Drug Deliv Rev (2014) 0.91
Tungsten oxide nanorods: an efficient nanoplatform for tumor CT imaging and photothermal therapy. Sci Rep (2014) 0.83
Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery. Drug Discov Today (2014) 0.82
Current and future trends in the anatomical and functional imaging of head and neck paragangliomas. Semin Nucl Med (2013) 0.82
Preparation and long-term biodistribution studies of a PAMAM dendrimer G5-Gd-BnDOTA conjugate for lymphatic imaging. Nanomedicine (Lond) (2014) 0.81
Supramolecular PEGylated Dendritic Systems as pH/Redox Dual-Responsive Theranostic Nanoplatforms for Platinum Drug Delivery and NIR Imaging. Theranostics (2016) 0.75
Tumor targeting, trifunctional dendritic wedge. Bioconjug Chem (2014) 0.75
Remotely Triggered Nano-Theranostics For Cancer Applications. Nanotheranostics (2017) 0.75
Active targeted drug delivery for microbes using nano-carriers. Curr Top Med Chem (2015) 0.75
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science (1990) 35.96
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
In vitro selection of RNA molecules that bind specific ligands. Nature (1990) 30.19
Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med (1991) 19.46
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res (1986) 15.83
Glutathione. Annu Rev Biochem (1983) 15.18
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 13.94
Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science (1994) 12.83
Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev (2003) 11.29
Looking and listening to light: the evolution of whole-body photonic imaging. Nat Biotechnol (2005) 9.57
Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 9.51
The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet (2007) 7.92
The dawning era of polymer therapeutics. Nat Rev Drug Discov (2003) 7.86
Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A (1998) 7.78
Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev (2002) 7.05
The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med (2008) 5.74
Imaging of angiogenesis: from microscope to clinic. Nat Med (2003) 5.51
Lymphatic metastasis in the absence of functional intratumor lymphatics. Science (2002) 5.32
Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev (2004) 5.31
Non-invasive optical spectroscopy and imaging of human brain function. Trends Neurosci (1997) 5.12
Designing dendrimers for biological applications. Nat Biotechnol (2005) 4.92
Tumor regression by targeted gene delivery to the neovasculature. Science (2002) 4.78
Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res (2004) 4.56
Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat Biotechnol (2001) 4.54
Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med (2008) 4.54
Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res (2002) 4.16
Cell adhesion and motility depend on nanoscale RGD clustering. J Cell Sci (2000) 4.13
Multiphoton microscopy in life sciences. J Microsc (2000) 4.12
Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med (2001) 4.02
Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A (2008) 3.62
Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res (1999) 3.58
Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem (2004) 3.57
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem (2004) 3.49
Dendrimers in biomedical applications--reflections on the field. Adv Drug Deliv Rev (2005) 3.39
Optical imaging of the heart. Circ Res (2004) 3.14
Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release (2000) 3.07
Selection in vitro of single-stranded DNA molecules that fold into specific ligand-binding structures. Nature (1992) 3.02
Fluorescence imaging in vivo: recent advances. Curr Opin Biotechnol (2007) 2.90
Aptamers as therapeutic and diagnostic agents. J Biotechnol (2000) 2.89
Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther (2002) 2.86
Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res (1997) 2.72
Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res (2003) 2.70
SELEXION. Systematic evolution of ligands by exponential enrichment with integrated optimization by non-linear analysis. J Mol Biol (1991) 2.64
Thiol/disulfide exchange equilibria and disulfide bond stability. Methods Enzymol (1995) 2.61
A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc Natl Acad Sci U S A (2006) 2.55
Functional polymers and dendrimers: reactivity, molecular architecture, and interfacial energy. Science (1994) 2.48
124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med (2003) 2.44
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell (2005) 2.37
Dendrimers and dendritic polymers in drug delivery. Drug Discov Today (2005) 2.37
Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev (2010) 2.37
Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res (2002) 2.30
Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev (2002) 2.27
Convergent dendrons and dendrimers: from synthesis to applications. Chem Rev (2001) 2.23
PET: the merging of biology and imaging into molecular imaging. J Nucl Med (2000) 2.15
Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer (1998) 2.15
[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med (2001) 2.11
Expression of the prostate-specific membrane antigen. Cancer Res (1994) 2.06
Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov Today (2010) 2.03
Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J Clin Invest (1999) 2.03
Integrins in invasive growth. J Clin Invest (2002) 1.96
(68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression. Eur J Nucl Med Mol Imaging (2008) 1.91
Nanoparticles as contrast agents for in-vivo bioimaging: current status and future perspectives. Anal Bioanal Chem (2010) 1.88
Targeting and inhibition of cell growth by an engineered dendritic nanodevice. J Med Chem (2005) 1.80
The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int J Pharm (2003) 1.80
Dendrimer-based nanoprobe for dual modality magnetic resonance and fluorescence imaging. Nano Lett (2006) 1.80
Controlled assembly of dendrimer-like DNA. Nat Mater (2003) 1.75
Molecular imaging with nanoparticles: giant roles for dwarf actors. Histochem Cell Biol (2008) 1.73
Retracted Tunable plasmonic nanoprobes for theranostics of prostate cancer. Theranostics (2011) 1.73
Encapsulation of guest molecules into a dendritic box. Science (1994) 1.72
Multimodal nanoprobes for radionuclide and five-color near-infrared optical lymphatic imaging. ACS Nano (2007) 1.70
Multimodality in vivo imaging systems: twice the power or double the trouble? Annu Rev Biomed Eng (2006) 1.68
Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs (1999) 1.67
Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res (2004) 1.66
Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med (2003) 1.61
Fluorescence imaging of tumors in vivo. Curr Med Chem (2005) 1.60
Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. J Biomed Mater Res (1996) 1.59
Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene (2001) 1.58
Tumor angiogenic vasculature targeting with PAMAM dendrimer-RGD conjugates. Chem Commun (Camb) (2005) 1.58
Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med (2003) 1.56
Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent. J Natl Cancer Inst (2004) 1.55
The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro. J Clin Invest (1997) 1.55
Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res (2005) 1.55
The in vivo behavior of copper-64-labeled azamacrocyclic complexes. Nucl Med Biol (1998) 1.52
Rhenium-186 liposomes as convection-enhanced nanoparticle brachytherapy for treatment of glioblastoma. Neuro Oncol (2012) 1.50
111In-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide analogues for melanoma imaging. Bioconjug Chem (2008) 1.48
Intestinal permeation enhancers. J Pharm Sci (2000) 1.44
Design, synthesis, and characterization of pH-sensitive PEG-PE conjugates for stimuli-sensitive pharmaceutical nanocarriers: the effect of substitutes at the hydrazone linkage on the ph stability of PEG-PE conjugates. Bioconjug Chem (2007) 1.43
A dendrimer-based nanosized contrast agent dual-labeled for magnetic resonance and optical fluorescence imaging to localize the sentinel lymph node in mice. J Magn Reson Imaging (2007) 1.43
Molecular imaging with theranostic nanoparticles. Acc Chem Res (2011) 1.41
Luminescent gold nanoparticles with efficient renal clearance. Angew Chem Int Ed Engl (2011) 1.41
Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style. Biomaterials (2009) 1.38
Surface acetylation of polyamidoamine (PAMAM) dendrimers decreases cytotoxicity while maintaining membrane permeability. Bioconjug Chem (2007) 1.36
64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: synthesis, radiolabeling, and biologic evaluation. J Nucl Med (2005) 1.35
Therapeutic and diagnostic applications of dendrimers for cancer treatment. Adv Drug Deliv Rev (2008) 1.35
Designing dendrimers for drug delivery. Pharm Sci Technolo Today (1999) 1.33
Optical imaging in drug discovery and diagnostic applications. Adv Drug Deliv Rev (2005) 1.33
Bimodal MR-PET agent for quantitative pH imaging. Angew Chem Int Ed Engl (2010) 1.32
BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med (2007) 4.50
Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem (2004) 3.57
Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci U S A (2013) 2.75
Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One (2009) 2.68
Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem (2005) 2.58
Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proc Natl Acad Sci U S A (2010) 2.16
Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. Nat Commun (2013) 2.11
Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol (2010) 2.05
Point-of-care platelet function testing predicts bleeding in patients exposed to clopidogrel undergoing coronary artery bypass grafting: Verify pre-op TIMI 45--a pilot study. Clin Cardiol (2015) 2.01
Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator. Clin Cancer Res (2004) 1.89
Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7. PLoS Pathog (2012) 1.88
Non-hepatic insults are common acute precipitants in patients with acute on chronic liver failure (ACLF). Dig Dis Sci (2010) 1.87
Synthesis, characterization, reactivity, and catalytic potential of model vanadium(IV, V) complexes with benzimidazole-derived ONN donor ligands. Inorg Chem (2006) 1.70
DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis. Proc Natl Acad Sci U S A (2009) 1.69
The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2. J Biol Chem (2002) 1.68
Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines (2010) 1.57
Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines. J Biol Chem (2002) 1.55
Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. Cancer (2006) 1.54
Mutation of SENP1/SuPr-2 reveals an essential role for desumoylation in mouse development. Mol Cell Biol (2005) 1.52
AIP1 mediates TNF-alpha-induced ASK1 activation by facilitating dissociation of ASK1 from its inhibitor 14-3-3. J Clin Invest (2003) 1.52
Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder. J Urol (2007) 1.52
Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. PLoS Comput Biol (2010) 1.51
Effect of Moringa oleifera Lam. leaves aqueous extract therapy on hyperglycemic rats. J Ethnopharmacol (2009) 1.48
Diospyrin derivative, an anticancer quinonoid, regulates apoptosis at endoplasmic reticulum as well as mitochondria by modulating cytosolic calcium in human breast carcinoma cells. Biochem Biophys Res Commun (2011) 1.47
Slitlamp, specular, and light microscopic findings of human donor corneas after laser-assisted in situ keratomileusis. Arch Ophthalmol (2004) 1.46
Nodal signaling recruits the histone demethylase Jmjd3 to counteract polycomb-mediated repression at target genes. Sci Signal (2010) 1.45
Design of a bioactive small molecule that targets the myotonic dystrophy type 1 RNA via an RNA motif-ligand database and chemical similarity searching. J Am Chem Soc (2012) 1.44
Selective prostate cancer thermal ablation with laser activated gold nanoshells. J Urol (2007) 1.42
Luminescent gold nanoparticles with efficient renal clearance. Angew Chem Int Ed Engl (2011) 1.41
Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer. Clin Cancer Res (2004) 1.39
Chemical composition of root aroma of Decalepis arayalpathra (J. Joseph and V. Chandras.) Venter, an endemic and endangered ethnomedicinal plant from Western Ghats, India. Nat Prod Res (2014) 1.39
Phosphoinositide 3-kinase gamma participates in T cell receptor-induced T cell activation. J Exp Med (2007) 1.38
64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: synthesis, radiolabeling, and biologic evaluation. J Nucl Med (2005) 1.35
The role of cell adhesion molecule in cancer progression and its application in cancer therapy. Acta Biochim Pol (2004) 1.35
Ultralight multiwalled carbon nanotube aerogel. ACS Nano (2010) 1.32
The role of Cdk5 in neuroendocrine thyroid cancer. Cancer Cell (2013) 1.30
Double-stranded RNA-mediated gene silencing of cysteine proteases (falcipain-1 and -2) of Plasmodium falciparum. Mol Microbiol (2002) 1.29
Phosphoinositide 3-kinase controls early and late events in mammalian cell division. EMBO J (2006) 1.28
Differential regulation of the human gene DAB2IP in normal and malignant prostatic epithelia: cloning and characterization. Genomics (2002) 1.28
Downregulation of human DAB2IP gene expression in prostate cancer cells results in resistance to ionizing radiation. Cancer Res (2010) 1.26
Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India. Indian J Med Res (2008) 1.25
A PI3K activity-independent function of p85 regulatory subunit in control of mammalian cytokinesis. EMBO J (2006) 1.24
Glucose metabolism via the pentose phosphate pathway, glycolysis and Krebs cycle in an orthotopic mouse model of human brain tumors. NMR Biomed (2012) 1.23
p53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3. Oncogene (2002) 1.22
Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation. Cancer Res (2010) 1.20
Effects of cerium oxide nanoparticles on the growth of keratinocytes, fibroblasts and vascular endothelial cells in cutaneous wound healing. Biomaterials (2012) 1.20
Phosphoinositide 3-kinases p110alpha and p110beta regulate cell cycle entry, exhibiting distinct activation kinetics in G1 phase. Mol Cell Biol (2008) 1.20
Haplotypes, loss of heterozygosity, and expression levels of glycine N-methyltransferase in prostate cancer. Clin Cancer Res (2007) 1.18
The role of the size and number of polyethylene glycol chains in the biodistribution and tumor localization of triazine dendrimers. Mol Pharm (2008) 1.18
Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome. Hum Pathol (2007) 1.18
Specific function of phosphoinositide 3-kinase beta in the control of DNA replication. Proc Natl Acad Sci U S A (2009) 1.17
Nanoscale control of phase variants in strain-engineered BiFeO₃. Nano Lett (2011) 1.16
A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo. PLoS One (2012) 1.15
Unveiling the mechanism of uptake and sub-cellular distribution of cerium oxide nanoparticles. Mol Biosyst (2010) 1.15
Imparting multivalency to a bifunctional chelator: a scaffold design for targeted PET imaging probes. Angew Chem Int Ed Engl (2009) 1.14
Near-infrared emitting radioactive gold nanoparticles with molecular pharmacokinetics. Angew Chem Int Ed Engl (2012) 1.14
Proteomic investigations of lysine acetylation identify diverse substrates of mitochondrial deacetylase sirt3. PLoS One (2012) 1.13
Acute myocardial infarction due to blunt chest trauma. Indian Heart J (2003) 1.13
Transplantation of mesenchymal stem cells from young donors delays aging in mice. Sci Rep (2011) 1.13
Cerium oxide nanoparticles scavenge nitric oxide radical (˙NO). Chem Commun (Camb) (2012) 1.13
Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties. J Cancer Res Clin Oncol (2012) 1.12
Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer. J Biol Chem (2002) 1.12
Proteomic analysis of Chinese hamster ovary cells. J Proteome Res (2012) 1.11
Acute exposure of uranyl nitrate causes lipid peroxidation and histopathological damage in brain and bone of Wistar rat. J Environ Pathol Toxicol Oncol (2007) 1.11
Treatment of overweight and obesity: lifestyle, pharmacologic, and surgical options. Clin Cornerstone (2009) 1.10
The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer. Cancer Res (2005) 1.08
Re: Degirmenci et al.: Outcomes of ureteroscopy for the management of impacted ureteral calculi with different localizations (Urology 2012;80:811-815). Urology (2013) 1.08
p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis (2002) 1.08
MRI detection of VEGFR2 in vivo using a low molecular weight peptoid-(Gd)8-dendron for targeting. J Am Chem Soc (2010) 1.08
Loop-mediated isothermal amplification of DNA (LAMP): a new diagnostic tool lights the world of diagnosis of animal and human pathogens: a review. Pak J Biol Sci (2014) 1.07
BF3 x OEt2-mediated highly regioselective S(N)2-type ring-opening of N-activated aziridines and N-activated azetidines by tetraalkylammonium halides. J Org Chem (2010) 1.07
PI3K/Akt to GSK3β/β-catenin signaling cascade coordinates cell colonization for bladder cancer bone metastasis through regulating ZEB1 transcription. Cell Signal (2012) 1.07
Re: Koraitim: predictors of erectile dysfunction post pelvic fracture urethral injuries: a multivariate analysis (Urology 2013;81:1081-1085). Urology (2013) 1.06
Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in human cultures established from mouse xenografts. Cancer Biol Ther (2011) 1.06
Caveolin-1 secreting LNCaP cells induce tumor growth of caveolin-1 negative LNCaP cells in vivo. Int J Cancer (2008) 1.06
Estimating perchlorate exposure from food and tap water based on US biomonitoring and occurrence data. J Expo Sci Environ Epidemiol (2010) 1.05
Antibacterial activities of poly(amidoamine) dendrimers terminated with amino and poly(ethylene glycol) groups. Biomacromolecules (2007) 1.05
PEGylated nanoceria as radical scavenger with tunable redox chemistry. J Am Chem Soc (2009) 1.05
Re: Lee et al.: factors indicating renal injury in pediatric bilateral ureteropelvic-junction obstruction (Urology 2013;81:873-879). Urology (2013) 1.05
Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer. Proc Natl Acad Sci U S A (2014) 1.04
Identification and phylogenetic analysis of orf viruses isolated from outbreaks in goats of Assam, a northeastern state of India. Virus Genes (2012) 1.04
The effect of the amide substituent on the biodistribution and tolerance of lanthanide(III) DOTA-tetraamide derivatives. Invest Radiol (2008) 1.04
Mobility after hospital discharge as a marker for 30-day readmission. J Gerontol A Biol Sci Med Sci (2012) 1.03
Positron emission tomography of copper metabolism in the Atp7b-/- knock-out mouse model of Wilson's disease. Mol Imaging Biol (2012) 1.03
Efficacy of ablative high-dose-per-fraction radiation for implanted human renal cell cancer in a nude mouse model. Eur Urol (2006) 1.03
The induction of angiogenesis by cerium oxide nanoparticles through the modulation of oxygen in intracellular environments. Biomaterials (2012) 1.03
Immunomodulatory and therapeutic potentials of herbal, traditional/indigenous and ethnoveterinary medicines. Pak J Biol Sci (2012) 1.02
In vitro evaluation of novel polymer-coated magnetic nanoparticles for controlled drug delivery. Nanomedicine (2010) 1.02
Novel synthetic ligands for targeted PET imaging and radiotherapy of copper. Bioorg Med Chem Lett (2007) 1.02
The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy. Int J Cancer (2007) 1.02
The relative cost of biomass energy transport. Appl Biochem Biotechnol (2007) 1.02
Peptoid-based PET imaging of vascular endothelial growth factor receptor (VEGFR) expression. Am J Nucl Med Mol Imaging (2011) 1.01
Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy. Mol Ther (2006) 1.01
Cytokine profile of conditioned medium from human tumor cell lines after acute and fractionated doses of gamma radiation and its effect on survival of bystander tumor cells. Cytokine (2012) 1.00
Epigenetic regulation of coxsackie and adenovirus receptor (CAR) gene promoter in urogenital cancer cells. Cancer Res (2003) 1.00
Autologous intravenous bone marrow mononuclear cell therapy for patients with subacute ischaemic stroke: a pilot study. Indian J Med Res (2012) 1.00